Abstract

Asthma is a highly prevalent inflammatory disease of the airways. Bacterial metabolites of soluble fibre fermentation, such as short chain fatty acids (SCFAs), have been shown to exert anti-inflammatory effects via free fatty acid receptor activation and epigenetic regulation through inhibition of histone deacetylases (HDACs). The aim of the present review was to summarise the available evidence for soluble fibre in the treatment and prevention asthma. There is substantial preclinical evidence suggesting soluble fibre may be beneficial in the airways. The clinical evidence in this area is limited, however available studies to date have reported promising evidence for the future of soluble fibre interventions as an adjunct treatment in asthma management.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.